PSS15 REAL-WORLD COSTS IN BIOLOGIC NAIVE PSORIATIC ARTHRITIS PATIENTS INITIATING APREMILAST OR BIOLOGICS IN A US HEALTHCARE CLAIMS DATABASE.

In all, 1,471 biologic-naive PsA patients initiating apremilast were matched to 890 biologic-naive PsA patients initiating biologics (TNF: n=804; IL: n=86). Biologic-naive PsA patients initiating apremilast had significantly lower healthcare costs than patients initiating biologics in a US claims database. [Extracted from the article]